abstract |
The present invention provides compositions and methods for treating ovarian cancer. Specifically, the present invention relates to administering a genetically modified T cell comprising an α-folate receptor (FRα) binding domain and a 4-1BB (CD137) costimulatory domain to treat ovarian cancer. |